Avidity Biosciences/$RNA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Avidity Biosciences

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Ticker

$RNA
Primary listing

Industry

Biotechnology

Employees

391

ISIN

US05370A1088

RNA Metrics

BasicAdvanced
$4B
-
-$3.03
0.99
-

What the Analysts think about RNA

Analyst ratings (Buy, Hold, Sell) for Avidity Biosciences stock.

Bulls say / Bears say

Avidity Biosciences expanded its collaboration with Bristol Myers Squibb in November 2023, focusing on up to five cardiovascular targets, with potential milestone payments up to $2.2 billion. (biospace.com)
The company reported a strong cash position of approximately $1.4 billion as of March 31, 2025, providing a solid financial foundation for ongoing and future projects. (aijourn.com)
Avidity announced positive data for AOC 1044 in December 2023, showing unprecedented delivery to muscle and up to 1.5% exon skipping in healthy volunteers, indicating potential efficacy in treating Duchenne muscular dystrophy. (themalaysianreserve.com)
Avidity reported an accumulated deficit of $710.4 million as of June 30, 2024, reflecting significant ongoing losses that may concern investors. (marketinference.com)
The company's research and development expenses increased to $99.5 million in Q1 2025 from $66.8 million in Q1 2024, indicating rising costs that could impact profitability. (aijourn.com)
Avidity's collaboration revenue decreased to $1.6 million in Q1 2025 from $3.5 million in Q1 2024, suggesting potential challenges in partnership-driven income. (aijourn.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

RNA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RNA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RNA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs